Bogliolo G, Massa G, Sobrero A, Pannacciulli I
Tumori. 1982 Aug;68(4):277-82. doi: 10.1177/030089168206800401.
The alleged possibility that testosterone propionate (TP) has a protective effect on hemopoietic cells submitted to the damaging effect of antitumoral drugs was studied. The bone marrow content and the proliferating fraction of CFUs were determined following a single dose on 450 mg/kg of TP. At selected times after TP injection (2 and 4 days), TP-treated mice received a single dose of azathioprine, hydroxyurea, vinblastine, cyclophosphamide, BCNU and doxorubicin. The bone marrow of CFUs were determined 24 h after drug administration. The CFUs-surviving fraction in all cases appeared similar to or lower than that found in controls not treated with TP. It seems therefore that in this experimental setting TP does not reduce the toxic effect of anticancer drugs on hemopoietic pluripotent stem cells. However, this finding does not exclude a possible protective effect of TP at different levels of hemopoiesis or when the steroid is administered with a different schedule.
研究了丙酸睾酮(TP)对受抗肿瘤药物损伤作用影响的造血细胞具有保护作用这一所谓的可能性。在给予450mg/kg的TP单剂量后,测定骨髓含量和CFU的增殖分数。在TP注射后的选定时间(2天和4天),接受TP治疗的小鼠接受单剂量的硫唑嘌呤、羟基脲、长春碱、环磷酰胺、卡氮芥和阿霉素。在给药后24小时测定CFU的骨髓情况。在所有情况下,CFU存活分数似乎与未用TP治疗的对照组相似或更低。因此,在这种实验环境中,TP似乎不会降低抗癌药物对造血多能干细胞的毒性作用。然而,这一发现并不排除TP在不同造血水平或当以不同给药方案给予类固醇时可能具有的保护作用。